Cytokine expression during acute graft-versus-host disease after allogeneic peripheral stem cell transplantation-Reference-Cited by-同舟云学术

Cytokine expression during acute graft-versus-host disease after allogeneic peripheral stem cell transplantation

Published:2005-04-25 Issue:12 Volume:35 Page:1179-1186
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Ju X P,Xu B,Xiao Z P,Li J Y,Chen L,Lu S Q,Huang Z X

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1704972.pdf

Reference32 articles.

1. Blazar BR, Korngold R, Vallera DA et al. Recent advances in graft-versus-host disease prevention. Immunol Res 1997; 157: 79–109.

2. Ferrara JLM, Deeg HJ . Graft-versus-host disease. N Engl J Med 1991; 324: 667–674.

3. Jadus MR, Wepsic HT . The role of cytokines in graft-versus-host reaction and disease. Bone Marrow Transplant 1992; 10: 1–14.

4. Ferrara JLM . The cytokine modulation of acute graft-versus-host disease. Bone Marrow Transplant 1998; 21 (Suppl. 3): S13–S15.

5. Mosmann TR, Chrwinski H, Bond MW et al. Two types of murine helper T cell clone: 1. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348–2357.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation;World Journal of Biological Chemistry;2022-09-27

2. Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity;Frontiers in Immunology;2022-05-23

3. Prevention of acute graft‑vs.‑host disease by targeting glycolysis and mTOR pathways in activated T cells;Experimental and Therapeutic Medicine;2022-05-16

4. Human Wnt/β-Catenin Regulates Alloimmune Signaling during Allogeneic Transplantation;Cancers;2021-07-28

5. Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technology;Biotechnology and Bioengineering;2021-07-21